Tehran University of Medical Sciences Iranian Journal of Microbiology 2008-3289 18 5 2026 10 05 712 717 Peri Sohrabi Molla Yousefi Department of Medical Microbiology, Istanbul Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye 2026 06 17 2026 08 30 Background and Objectives: Candidemia is an important cause of healthcare-associated bloodstream infection, and changes in the distribution of Candida species may influence antifungal treatment strategies. This study aimed to determine the species distribution of yeasts isolated from blood cultures and evaluate their antifungal susceptibility profiles. Materials and Methods: This retrospective study included 269 yeast isolates recovered from blood cultures between December 2017 and December 2021. Species identification was performed using the VITEK 2 YST system. Antifungal susceptibility testing was performed using Sensititre YeastOne for 215 (79.9%) isolates and VITEK 2 AST-YS08 for 54 (20.1%). Minimum inhibitory concentration results were interpreted according to applicable CLSI species-specific clinical breakpoints. Results: Of the 269 isolates, 112 (41.6%) were Candida albicans and 157 (58.4%) were non-albicans Candida. The most frequent non-albicans species were C. parapsilosis (n=73, 27.1%), Nakaseomyces glabrata (C. glabrata) (n=37, 13.8%), and C. tropicalis (n=34, 12.6%). Fluconazole MIC50/MIC90 values were 0.5/256 mg/L for C. albicans, 1/16 mg/L for C. parapsilosis, 8/32 mg/L for C. glabrata, and 1/4 mg/L for C. tropicalis. Conclusion: The predominance of non-albicans Candida, particularly C. parapsilosis, highlights the importance of continuous local surveillance. Methodological differences between commercial susceptibility testing systems should be considered when interpreting antifungal susceptibility results. https://ijm.tums.ac.ir/index.php/ijm/article/view/6264 https://ijm.tums.ac.ir/index.php/ijm/article/download/6264/1932